INNO-206

For research use only. Not for therapeutic Use.

  • CAT Number: I001395
  • CAS Number: 1361644-26-9
  • Molecular Formula: C37H42N4O13
  • Molecular Weight: 750.75
  • Purity: ≥95%
Inquiry Now

INNO-206(Cat No.:I001395), also known as aldoxorubicin, is a novel prodrug of the anthracycline chemotherapeutic agent doxorubicin. It is designed to improve the therapeutic index of doxorubicin by selectively delivering it to tumor tissues while minimizing exposure to healthy tissues. INNO-206 utilizes a linker technology that allows for the preferential release of doxorubicin in the tumor microenvironment, potentially reducing systemic toxicity. Preclinical studies have shown that INNO-206 has enhanced antitumor activity compared to doxorubicin in various cancer models. Clinical trials have evaluated its efficacy and safety in several cancer types, including soft tissue sarcoma and advanced pancreatic cancer. Further research is ongoing to explore its potential benefits in cancer treatment.


Catalog Number I001395
CAS Number 1361644-26-9
Synonyms

Aldoxorubicin; INNO-206; INNO206

Molecular Formula C37H42N4O13
Purity ≥95%
Target Antibody-drug Conjugate/ADC Related
Solubility 10 mM in DMSO
Storage Store at -20°C
Overview of Clinical Research

Originator: KTB Tumorforschungs<br />
Developer: CytRx Corporation<br />
Class: Anthracyclines; Cytostatic antibiotics; Doxorubicins; Hydrazines; Maleimides; Pyrroles; Small molecules<br />
Mechanism of Action: DNA intercalators; Reactive oxygen species stimulants; Type II DNA topoisomerase inhibitors<br />
Orphan Drug Status: Yes – Small cell lung cancer; Soft tissue sarcoma; Pancreatic cancer; Glioblastoma; Ovarian cancer<br />
New Molecular Entity: No<br />

IUPAC Name N-[(E)-[1-[(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-hydroxyethylidene]amino]-6-(2,5-dioxopyrrol-1-yl)hexanamide
InChI InChI=1S/C37H42N4O13/c1-17-32(46)20(38)13-27(53-17)54-22-15-37(51,23(16-42)39-40-24(43)9-4-3-5-12-41-25(44)10-11-26(41)45)14-19-29(22)36(50)31-30(34(19)48)33(47)18-7-6-8-21(52-2)28(18)35(31)49/h6-8,10-11,17,20,22,27,32,42,46,48,50-51H,3-5,9,12-16,38H2,1-2H3,(H,40,43)/b39-23+/t17-,20-,22-,27-,32+,37-/m0/s1
InChIKey OBMJQRLIQQTJLR-USGQOSEYSA-N
SMILES C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(/C(=N/NC(=O)CCCCCN6C(=O)C=CC6=O)/CO)O)N)O
Reference

1: Sachdev E, Sachdev D, Mita M. Aldoxorubicin for the treatment of soft tissue sarcoma. Expert Opin Investig Drugs. 2017 Oct;26(10):1175-1179. doi: 10.1080/13543784.2017.1371134. Epub 2017 Aug 28. Review. PubMed PMID: 28846045.<br />
2: Chugh R, Schuetze SM. Aldoxorubicin in Sarcoma: Teaching an Old Drug New Tricks. JAMA Oncol. 2015 Dec;1(9):1280-1. doi: 10.1001/jamaoncol.2015.3221. PubMed PMID: 26379207.<br />
3: Chawla SP, Papai Z, Mukhametshina G, Sankhala K, Vasylyev L, Fedenko A, Khamly K, Ganjoo K, Nagarkar R, Wieland S, Levitt DJ. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial. JAMA Oncol. 2015 Dec;1(9):1272-80. doi: 10.1001/jamaoncol.2015.3101. PubMed PMID: 26378637.<br />
4: Mita MM, Natale RB, Wolin EM, Laabs B, Dinh H, Wieland S, Levitt DJ, Mita AC. Pharmacokinetic study of aldoxorubicin in patients with solid tumors. Invest New Drugs. 2015 Apr;33(2):341-8. doi: 10.1007/s10637-014-0183-5. Epub 2014 Nov 12. PubMed PMID: 25388939; PubMed Central PMCID: PMC4387275.<br />
5: Chawla SP, Chua VS, Hendifar AF, Quon DV, Soman N, Sankhala KK, Wieland DS, Levitt DJ. A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma. Cancer. 2015 Feb 15;121(4):570-9. doi: 10.1002/cncr.29081. Epub 2014 Oct 13. PubMed PMID: 25312684.<br />
6: Marrero L, Wyczechowska D, Musto AE, Wilk A, Vashistha H, Zapata A, Walker C, Velasco-Gonzalez C, Parsons C, Wieland S, Levitt D, Reiss K, Prakash O. Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastoma. Neoplasia. 2014 Oct 23;16(10):874-82. doi: 10.1016/j.neo.2014.08.015. eCollection 2014 Oct. PubMed PMID: 25379024; PubMed Central PMCID: PMC4212249.

Request a Quote